Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates

Kraft O, Kaspárek R, Ullmann V, Melichar F, Kropácek M, Mirzajevova M

. 2007 ; 22 (2) : 296-302.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky

Perzistentní odkaz   https://www.medvik.cz/link/bmc10001006
E-zdroje Online

NLK ProQuest Central od 2000-04-01 do 2018-12-31
Health & Medicine (ProQuest) od 2000-04-01 do 2018-12-31
Public Health Database (ProQuest) od 2000-04-01 do 2018-12-31

The aim of this study was to evaluate adverse and therapeutic effects of applicated holmium-boro-macroaggregates (HBMAs) in the radiosynoviorthesis (RSO) of knees in patients suffering from chronic synovitis. We started RSO of the knees by means of a new radiopharmaceutical (RF) HBMA in patients with gonarthrosis, rheumatoid arthritis, chronic synovitis, psoriatic arthritis, and gout arthropathy. Seventeen (17) intra-articular injections were performed in 15 patients who were receiving a mean activity of 972 MBq (range, 904-1057) of 166Ho-HBMA. Patient inclusion to the study followed a series of inclusion and exclusion criterions. The patients were hospitalized for 3 days. Side-effects were evaluated during their hospital stay and again after 6-8 weeks. Static scintigraphy of knee joints and measurements of blood radioactivity were performed. Therapeutic effects were evaluated after 6-8 weeks and at 6 months. In 2 hours and 2 days following the application, we proved, by means of knee and inguinal scintigraphy, only insignificant radiopharmaceutical leakage from the joint cavity to the inguinal lymph nodes in 4 patients. In the treated patients, no serious adverse effects occurred. Nine (9) patients were without complaints, 4 patients had slight knee exudation, and 2 patients had great exudation. Therapeutic effects were as follows: 2 patients were without pain, 9 were with lower pain, 3 were with the same pain, and 1 patient was with increased pain. Joint motion was improved in 7 patients, remained the same in 7 patients, and was impaired in 1 patient. Analgesics consumption was lower in 5 patients, the same in 9 patients, and greater in 1 patient. Knee exudation was absent in 2 patients, lower in 4 patients, the same in 6 patients, and greater in 3 patients. In 3 patients it was necessary to do surgical RSO. This RF can extend the range of clinically used radiopharmaceuticals for RSO and to supplement space between 90Y with high energy and 186Re with 169Er with lower beta energy. The energy of 166Ho is suitable for great and medium joints (i.e., knees, hips, shoulders, elbows, wrists, and ankles).

000      
00000naa 2200000 a 4500
001      
bmc10001006
003      
CZ-PrNML
005      
20111210154843.0
008      
100117s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kraft, Otakar, $d 1953- $7 xx0083594
245    10
$a Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates / $c Kraft O, Kaspárek R, Ullmann V, Melichar F, Kropácek M, Mirzajevova M
314    __
$a Department of Nuclear Medicine, University Hospital, Ostrava-Poruba, Czech Republic. otakar.kraft@fnspo.cz
520    9_
$a The aim of this study was to evaluate adverse and therapeutic effects of applicated holmium-boro-macroaggregates (HBMAs) in the radiosynoviorthesis (RSO) of knees in patients suffering from chronic synovitis. We started RSO of the knees by means of a new radiopharmaceutical (RF) HBMA in patients with gonarthrosis, rheumatoid arthritis, chronic synovitis, psoriatic arthritis, and gout arthropathy. Seventeen (17) intra-articular injections were performed in 15 patients who were receiving a mean activity of 972 MBq (range, 904-1057) of 166Ho-HBMA. Patient inclusion to the study followed a series of inclusion and exclusion criterions. The patients were hospitalized for 3 days. Side-effects were evaluated during their hospital stay and again after 6-8 weeks. Static scintigraphy of knee joints and measurements of blood radioactivity were performed. Therapeutic effects were evaluated after 6-8 weeks and at 6 months. In 2 hours and 2 days following the application, we proved, by means of knee and inguinal scintigraphy, only insignificant radiopharmaceutical leakage from the joint cavity to the inguinal lymph nodes in 4 patients. In the treated patients, no serious adverse effects occurred. Nine (9) patients were without complaints, 4 patients had slight knee exudation, and 2 patients had great exudation. Therapeutic effects were as follows: 2 patients were without pain, 9 were with lower pain, 3 were with the same pain, and 1 patient was with increased pain. Joint motion was improved in 7 patients, remained the same in 7 patients, and was impaired in 1 patient. Analgesics consumption was lower in 5 patients, the same in 9 patients, and greater in 1 patient. Knee exudation was absent in 2 patients, lower in 4 patients, the same in 6 patients, and greater in 3 patients. In 3 patients it was necessary to do surgical RSO. This RF can extend the range of clinically used radiopharmaceuticals for RSO and to supplement space between 90Y with high energy and 186Re with 169Er with lower beta energy. The energy of 166Ho is suitable for great and medium joints (i.e., knees, hips, shoulders, elbows, wrists, and ankles).
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a holmium $x škodlivé účinky $x terapeutické užití $7 D006695
650    _2
$a lidé $7 D006801
650    _2
$a koleno $x patologie $x účinky záření $7 D007717
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a synovitida $x patologie $x radioterapie $7 D013585
650    _2
$a časové faktory $7 D013997
655    _2
$a klinické zkoušky $7 D016430
700    1_
$a Kašpárek, Richard $7 xx0100981
700    1_
$a Ullmann, Vojtěch, $d 1949- $7 jk01140714
700    1_
$a Melichar, František $7 xx0053036
700    1_
$a Kropáček, Martin $7 xx0166212
700    1_
$a Mirzajevová, Marcela $7 xx0166211
773    0_
$w MED00008725 $t Cancer biotherapy & radiopharmaceuticals $g Roč. 22, č. 2 (2007), s. 296-302 $x 1084-9785
910    __
$a ABA008 $b x $y 8
990    __
$a 20100114083259 $b ABA008
991    __
$a 20100215142952 $b ABA008
999    __
$a ok $b bmc $g 703734 $s 566176
BAS    __
$a 3
BMC    __
$a 2007 $b 22 $c 2 $d 296-302 $i 1084-9785 $m Cancer biotherapy & radiopharmaceuticals $x MED00008725
LZP    __
$a 2010-b1/vtme

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...